Small-Cap Biotech Opportunity Knocks

Among the most beaten-down assets in the first month of 2022 were biotechnology stocks, with smaller members of that group enduring significant punishment. That’s the bad news. The good news is that exchange traded funds, such as the ALPS Medical Breakthroughs ETF (SBIO), may be offering...